Creating new antibodies to target cancer cells
Developing therapeutic TCR mimic monoclonal antibodies for cancer
This study is working on a new type of antibody that can better target and attack cancer cells, especially in cases like cervical cancer, by recognizing special markers on the cancer cells, which could lead to more effective treatments with fewer side effects for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10908584 on NIH RePORTER |
What this research studies
This research focuses on developing a new class of monoclonal antibodies known as T cell receptor mimic (TCRm) antibodies, which can specifically target cancer cells by recognizing unique peptides displayed on their surface. Unlike traditional antibodies that bind to surface proteins, TCRm antibodies can access a broader range of tumor-specific antigens derived from intracellular proteins. The project aims to create TCRm antibodies that are effective against specific cancer types, such as cervical cancer, by combining the specificity of T cell recognition with the therapeutic benefits of monoclonal antibodies. This innovative approach could enhance the effectiveness of cancer treatments while minimizing side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cervical cancer or other cancers that express the targeted tumor-specific antigens.
Not a fit: Patients with cancers that do not express the specific antigens targeted by the TCRm antibodies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer therapies with fewer side effects for patients.
How similar studies have performed: Other research has shown promising results with similar approaches using monoclonal antibodies to target cancer, indicating potential for success in this novel application.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Dao, Tao — Sloan-Kettering Inst Can Research
- Study coordinator: Dao, Tao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.